Mumbai, India, October 06, 2022:Glenmark Pharmaceuticals Limited (Glenmark), an innovation‐driven global pharmaceutical company, became the first to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) in India for the treatment of type 2 diabetes in adults. Marketed under the brand name LOBG; it contains Lobeglitazone (0.5 mg) and to be taken once daily under prescription to improve glycemic control in adult diabetic patients. Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin‐resistant diabetic patients. Glenmark earlier received approval from the Indian drug regulator, Drug Controller General of India, for manufacturing and marketing Lobeglitazone based on a randomized, double‐blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older. The results of this trial have shown a faster and improved glycemic control with Lobeglitazone.   On the occasion of the launch, Alok Malik, EVP & Business Head  ‐  India Formulations, Glenmark Pharmaceuticals, said, “As per the International Diabetes Federation, diabetes affects 74 million adults in India, of which, around 40% of them seem to be insulin‐resistant. As a leading solutions provider in India for the treatment of diabetes, we are proud to introduce LOBG; an innovative and affordable drug, which will help in tackling insulin resistance among adult patients suffering from uncontrolled Type 2 diabetes in the country.” Glenmark and Diabetes in India Glenmark has a strong legacy of bringing new and effective treatment options for diabetic patients. In 2015, Glenmark revolutionized diabetes treatment in India by being the first to launch the DPP4 inhibitor – Teneligliptin, followed by a fixed dose combination of Teneligliptin + Metformin. In continuation towards its legacy, Glenmark launched Remogliflozin, a novel SGLT‐2 inhibitor in 2019 after itsfirst global approval in India and subsequently launched its combinations with metformin and Vildagliptin.   According to IQVIA™ sales data for the 12‐month period ending Aug. 2022, the market for oral anti‐diabetic drugs in India is estimated to be INR 11,725 cr. with an annual growth of 7% against the corresponding period last year (MAT Aug 2021). As per the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045i . Out of these, 77% of patients have uncontrolled diabetes. Moreover every four out of ten diabetic patients seem to have insulin resistance in Indiaii . ‐‐‐End‐‐‐  About Glenmark Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation‐driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world‐class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies(Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off‐patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets(2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com, LinkedIn (Glenmark Pharmaceuticals), Instagram (glenmark_pharma). For more information, please contact Udaykumar Murthy | +91 9960377617 | corpcomm@glenmarkpharma.com References i https://www.diabetesatlas.org/data/en/country/93/in.html ii Anjana RM et al. BMJ Open Diabetes Research and Care. 2020 Aug 1;8(1):e001506